Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China
Press Release – Oslo, Norway, November 4, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today on the treatment of the first patient in the Hexvix[®] phase III bridging trial.The objective of the multicenter Phase III trial is to achieve regulatory approval of Hexvix in Mainland China for use in patients with bladder cancer, by investigating the detection rate and safety of Hexvix and blue light cystoscopy (BLC[®]) versus white light cystoscopy in patients with non-muscle invasive bladder cancer (